MD Anderson Cancer Center Uni of Te MDACC
Welcome,         Profile    Billing    Logout  
 4 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Drappatz, Jan
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03212274: Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
2
145
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
07/24
07/24
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
INSIGhT, NCT02977780: INdividualized Screening Trial of Innovative Glioblastoma Therapy

Recruiting
2
250
US
Temozolomide, Temodar, Neratinib, QBS10072S
Patrick Wen, MD, Eli Lilly and Company, Celgene, Puma Biotechnology, Inc., Accelerate Brain Cancer Cure, Quadriga Biosciences, Inc.
Glioblastoma
03/25
12/25
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
NCT05736406: A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

Recruiting
1/2
12
US
5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, Pentalafen®, 5-aminolevulinic acid hydrochloride, Heliance® Solution, 5-ALA PDT, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
Hemerion Therapeutics
Primary Glioblastoma
03/25
07/25
NCT05109728: A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Recruiting
1
60
Europe, US
[177Lu]Lu-DOTA-TATE, Lutathera, Lutetium (177Lu)oxodotreotide, Lutetium Lu 177dotatate, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy
Novartis Pharmaceuticals
Glioblastoma
07/25
07/26
NCT03423628: A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Calendar Jan 2024 - Dec 2024: Data from trial in combination with radiation therapy for brain metastases
Recruiting
1
120
Europe, US
Radiation Therapy, Radiotherapy, Radiation treatment, RT, AZD1390, ATM inhibitor
AstraZeneca
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
04/26
04/26
Drokin, Ashley
NCT04058756: Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Recruiting
1
121
Europe, Canada, US, RoW
PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors
04/30
04/30

Download Options